Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

Background: Xevinapant, an inhibitor of apoptosis protein (IAP) inhibitor, has shown promising activity in combination with anticancer agents, including radiotherapy, and, in preclinical studies, anti-PD-(L)1 antibodies. This, in part, is due to its ability to restore apoptosis and increase antitumo...

Full description

Saved in:
Bibliographic Details
Main Authors: Glenwood Goss, Tudor Ciuleanu, Rodryg Ramlau, Daniel J. Renouf, Quincy Chu, Ewa Kalinka, Piotr Sawrycki, Jonathan Bramson, Brad H. Nelson, Rafael Crabbé, Eric LaCasse, Bryan Lo, Daniela A. Sahlender, Philippa Crompton, Franck Brichory, Luke Piggott, Michael Schenker, Rosalyn Juergens
Format: Article
Language:English
Published: SAGE Publishing 2025-05-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359251332154
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1177/17588359251332154

Similar Items